A large investigation found that more than half of patients receiving cellular therapies experience orthostatic hypotension, with most cases occurring within the first month. The study describes the condition as a clinically important, often under-recognized cardiovascular complication of post-infusion care. The findings are likely to affect monitoring protocols and early intervention strategies during the high-risk window for cellular therapy recipients. For CD19/CD22 CAR-T and allogeneic transplant programs alike, the study emphasizes that supportive care design is becoming part of the differentiation strategy, not just adverse-event reporting.